- Dynavax Technologies (DVAX, Financial) reports strong Q1 2025 financial results with significant growth in revenue.
- HEPLISAV-B® achieves 43% U.S. market share, driving substantial year-over-year revenue growth.
- Company completes $172M of its $200M share repurchase program and announces new vaccine pipeline initiatives.
Dynavax Technologies (DVAX) has issued a response to Deep Track Capital's investor presentation, reaffirming its strong Q1 2025 financial performance and urging stockholders to support its nominated directors at the upcoming annual meeting. The company reported total revenues of $68.2 million for Q1 2025, marking a 34% year-over-year increase. HEPLISAV-B® alone contributed $65 million, representing a 36% rise from the previous year.
HEPLISAV-B® has impressively captured approximately 43% of the U.S. market share, underscoring its dominance in the hepatitis B vaccine segment. Furthermore, Dynavax has completed 85% of its $200 million share repurchase program, reflecting its commitment to returning value to shareholders.
In addition to its financial achievements, Dynavax has announced two new pipeline programs: a Pandemic Influenza vaccine, set to enter Phase 1/2 trials in Q2 2025, and a Lyme Disease vaccine expected to begin clinical development in 2027. These initiatives underscore Dynavax's strategic focus on expanding its vaccine portfolio to address unmet medical needs.
The company is currently engaged in a proxy battle with Deep Track Capital, which is advocating for board changes and increased capital returns. Dynavax has urged stockholders to vote in favor of its four director nominees, asserting that Deep Track's proposals could undermine long-term value creation.
Dynavax's strategic execution has resulted in a 203% return to shareholders over the past five years, significantly outperforming its vaccine industry peers and the broader S&P Biotech Index. This robust performance highlights Dynavax's effective capital allocation strategy and commitment to sustainable growth.
